00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
23:36 , Nov 22, 2016 |  BC Week In Review  |  Clinical News

Amphetamine XR oral suspension regulatory udpate

Neos submitted an NDA to FDA for NT-0201 to treat ADHD. The product is an oral suspension extended-release amphetamine polistirex using Neos’ dynamic time release suspension (DTRS) technology. Neos Therapeutics Inc. (NASDAQ:NEOS), Grand Prairie, Texas ...